Table 3

Main findings (primary outcomes).

All-cause mortality

Myocardial infarction

Stroke


Diuretics vs.BB

0.90 (0.80 to 1.01)

0.82 (0.68 to 0.98)

0.83 (0.68 to 1.07)


⊕ ⊕ ⊕ O

⊕ ⊕ OO

⊕ ⊕ OO


Diuretics vs. ACE

1.00 (0.93 to 1.08)

1.00 (0.88 to 1.15)

0.94 (0.81 to 1.10)


⊕ ⊕ ⊕ O

⊕ ⊕ ⊕ O

⊕ ⊕ ⊕ O


Diuretics vs. CCB

1.03 (0.96 to 1.10)

0.96 (0.84 to 1.07)

1.12 (0.97 to 1.29)


⊕ ⊕ ⊕ O

⊕ ⊕ ⊕ O

⊕ ⊕ OO


Diuretics vs.alpha-blockers

0.98 (0.87 to 1.12)

0.99 (0.80 to 1.23)

0.85 (0.66 to 1.12)


⊕ ⊕ ⊕ O

⊕ ⊕ ⊕ O

⊕ ⊕ OO


Diuretics vs.ARB

1.02 (0.92 to 1.14)

0.83 (0.69 to 1.03)

1.02 (0.82 to 1.28)


⊕ ⊕ OO

⊕ OOO

⊕ OOO


BB vs. ACE

1.12 (0.98 to 1.27)

1.22 (1.00 to 1.52)

1.13 (0.86 to 1.42)


⊕ OOO

⊕ ⊕ OO

⊕ OOO


BB vs. CCB

1.14 (1.01 to 1.28)

1.17 (0.97 to 1.42)

1.34 (1.05 to 1.64)


⊕ ⊕ OO

⊕ OOO

⊕ ⊕ OO


BB vs. alpha-blockers

1.09 (0.93 to 1.30)

1.20 (0.92 to 1.61)

1.02 (0.71 to 1.42)


⊕ OOO

⊕ OOO

⊕ OOO


BB vs. ARB

1.14 (1.02 to 1.28)

1.02 (0.84 to 1.27)

1.23 (0.96 to 1.49)


⊕ ⊕ ⊕ ⊕

⊕ ⊕ ⊕ O

⊕ ⊕ ⊕ O


ACE vs. CCB

1.02 (0.95 to 1.10)

0.96 (0.83 to 1.07)

1.19 (1.03 to 1.38)


⊕ ⊕ ⊕ O

⊕ ⊕ ⊕ O

⊕ ⊕ ⊕ O


ACE vs. alpha-blockers

0.98 (0.85 to 1.14)

0.99 (0.77 to 1.27)

0.91 (0.67 to 1.24)


⊕ ⊕ OO

⊕ OOO

⊕ OOO


ACE vs. ARB

1.02 (0.91 to 1.14)

0.84 (0.68 to 1.04)

1.08 (0.86 to 1.37)


⊕ ⊕ OO

⊕ OOO

⊕ OOO


CCB vs. alpha-blockers

0.96 (0.83 to 1.11)

1.03 (0.82 to 1.34)

0.77 (0.57 to 1.04)


⊕ ⊕ OO

⊕ OOO

⊕ OOO


CCB vs. ARB

1.00 (0.91 to 1.10)

0.87 (0.74 to 1.06)

0.91 (0.75 to 1.11)


⊕ ⊕ ⊕ ⊕

⊕ ⊕ ⊕ O

⊕ ⊕ ⊕ O


Alpha-blockers vs. ARB

1.04 (0.88 to 1.23)

0.84 (0.63 to 1.14)

1.20 (0.85 to 1.69)


⊕ ⊕ OO

⊕ OOO

⊕ OOO


ACE, Angiotensin Converting Enzyme Inhibitors; ARB, Angiotensin Receptor Blockers; BB, Beta-blockers; CCB, Calcium Channel Blockers; ⊕ ⊕ ⊕ ⊕, High quality evidence; ⊕ ⊕ ⊕ O, Moderate quality evidence; ⊕ ⊕ OO, Low quality evidence; ⊕ OOO, Very low quality evidence

Fretheim et al. BMC Medicine 2012 10:33   doi:10.1186/1741-7015-10-33

Open Data